Sarepta settles REGENXBIO, UPenn patent litigation for USD 39 million
Bitget2026/09/23 20:14- Sarepta Therapeutics reached a settlement on Sept. 23, 2026 to resolve patent infringement litigation tied to AAVrh74-based gene therapies.
- Payment of USD 39 million due to REGENXBIO within 10 days; charge previously recorded for the quarter ended June 30, 2026.
- REGENXBIO and the University of Pennsylvania released claims through the effective date tied to certain AAVrh74-related patents.
- Non-suit commitments cover ELEVIDYS and other AAVrh74-based programs; REGENXBIO also agreed not to sue over patents covering existing ELEVIDYS.
- Cases to be dismissed with prejudice; no admission of liability; each party to cover its own legal costs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
